# **Product** Data Sheet

## AZD4625

Molecular Weight: 486.9
Target: Ras

Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years In solvent -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (205.38 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.0538 mL	10.2690 mL	20.5381 mL
	5 mM	0.4108 mL	2.0538 mL	4.1076 mL
	10 mM	0.2054 mL	1.0269 mL	2.0538 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility:  $\geq$  2.08 mg/mL (4.27 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\geq$  2.08 mg/mL (4.27 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	AZD4625 (Compound 21) is a highly potent, selective, covalent and allosteric inhibitor of the mutant GTPase KRAS <sup>G12C</sup> . AZD4625 has high oral bioavailability <sup>[1]</sup> .
IC <sub>50</sub> & Target	KRAS(G12C)

#### **REFERENCES**

1]. Kettle JG, et al. Discovery of	AZD4625, a Covalent Alloster	c Inhibitor of the Mutant GTPase K	RASG12C. J Med Chem. 2022 May 12;65(9):6	940-6952.
			al applications. For research use only.	
	Tel: 609-228-6898 Address: 1 D	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmouth	E-mail: tech@MedChemExpress.com n Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com